Fabomotizole

Fabomotizole

Chemical structure of Fabomotizole

Fabomotizole, also known as Afobazole, is a selective anxiolytic medication used primarily in Russia and some other countries for the treatment of anxiety disorders. It is known for its unique mechanism of action and favorable side effect profile compared to traditional benzodiazepines.

Mechanism of Action

Fabomotizole acts as a selective modulator of the sigma-1 receptor and has been shown to have neuroprotective and anxiolytic effects. Unlike benzodiazepines, it does not significantly affect the GABAergic system, which reduces the risk of sedation, muscle relaxation, and dependence.

Clinical Uses

Fabomotizole is primarily prescribed for the management of generalized anxiety disorder (GAD) and other anxiety-related conditions. It is also used in the treatment of neurasthenia and adjustment disorder.

Pharmacokinetics

Fabomotizole is administered orally and is rapidly absorbed from the gastrointestinal tract. It has a relatively short half-life, which contributes to its low potential for accumulation and side effects. The drug is metabolized in the liver and excreted primarily in the urine.

Side Effects

The side effect profile of Fabomotizole is generally mild. Common side effects include headache, dizziness, and gastrointestinal disturbances. Unlike benzodiazepines, it does not cause significant sedation or cognitive impairment.

Advantages over Benzodiazepines

Fabomotizole offers several advantages over traditional benzodiazepines, including:

• Lower risk of dependence and withdrawal symptoms
• Minimal sedation and cognitive impairment
• No significant interaction with alcohol

Related Pages

• Anxiolytic
• Sigma-1 receptor
• Generalized anxiety disorder
• Benzodiazepine